Aziyo Biologics (ELUT) has released an update.
On January 31, 2024, the Compensation Committee of Aziyo Biologics, Inc. approved a stock option repricing program for current employees and consultants, excluding executive officers and non-employee Board members. The repricing adjusted the exercise price of certain stock options to $3.61, aligning with the market price on the date of approval, without altering the original number of shares, vesting schedules, or expiration dates. Additionally, new incentive awards were granted to certain employees, including stock options and Restricted Stock Units (RSUs) with vesting conditions tied to company performance milestones and set timelines.
For further insights into ELUT stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
